Intellia Therapeutics, Inc.
NTLAIntellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
Drugs in Pipeline
4
Phase 3 Programs
3
Upcoming Catalysts
4
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
4 upcoming, 0 past
NTLA Earnings Report
EPS Est: $-0.80 | FQ end 2026-06 | Call: 2026-08-06 15:00:00
3 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How NTLA's past catalysts played out
NTLA-2002
Hereditary Angioedema
NTLA-2001
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
nexiguran ziclumeran
Neuromuscular Disease
Biological NTLA-2002
Hereditary Angioedema
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NTLA-2002 | Phase 3 | Hereditary Angioedema | - | - |
NTLA-2001 | Phase 3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | - | - |
nexiguran ziclumeran | Phase 3 | Neuromuscular Disease | - | - |
Biological NTLA-2002 | Phase 2 | Hereditary Angioedema | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Intellia Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Intellia Therapeutics, Inc.'s (NTLA) pipeline across Phase 3, Phase 2. Its lead program is NTLA-2002 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Intellia Therapeutics, Inc.'s next FDA catalyst?→
Intellia Therapeutics, Inc.'s (NTLA) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NTLA biotech catalysts?→
Add NTLA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Intellia Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.